Aspire RX, formerly RX Pro, makes its national debut
JACKSON, Miss., June 16, 2015 /PRNewswire/ -- There is a new face on one of the leading compounding pharmacies in the US with the launch of Aspire RX, a full service national pharmacy specializing in prescribed compounded transdermal medications.
Formerly known as RX Pro Pharmacy and Compounding, Aspire RX continues to serve licensed physicians nationwide by providing transdermal formulations for their patients that treat an array of ailments including pain, inflammation, viral infections, hormone insufficiency, erectile dysfunction, scar, wound, migraine, warts and more. Compounded transdermal medications are a safe alternative to oral medications, greatly limiting exposure to the GI tract, liver and kidneys with minimal absorption into the blood stream. Aspire RX formulations are non-narcotic, non-addictive and non-sedating, and have minimal adverse side effects and drug interaction risk.
"Transitioning to Aspire RX is the next step in our evolution to positively impact healthcare in our country," explains Jason Rutland, CEO. "It is a change that allows us to continue providing and developing effective, safe, quality medications that promote healing to patients nationwide."
The change follows a corporate restructuring to position parent company Aspire Health, LLC to broaden its base in the healthcare ecosystem by adding relevant vertical markets to its already thriving pharmacy practice.
Aspire RX is a division of Aspire Health, LLC, a privately held company headquartered in Jackson, MS and is licensed in all 50 states, with the ability to accept most major insurances. Aspire RX offers a broad spectrum of compounded products including capsules, solutions, injectables, and many others and specializes in the production of prescribed, compounded transdermal creams designed to meet a specific individual's unique medical needs.
SOURCE Aspire RX
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article